Check-Cap Ltd (7CC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Check-Cap Ltd (7CC) has a cash flow conversion efficiency ratio of -0.149x as of December 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.54 Million ≈ $-4.14 Million USD) by net assets (€23.69 Million ≈ $27.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Check-Cap Ltd (7CC) market capitalisation for the company's overall valuation and market capitalisation.
Check-Cap Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Check-Cap Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Check-Cap Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Check-Cap Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Check-Cap Ltd to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Solarmax Technology Inc. Common Stock
NASDAQ:SMXT
|
367.037x |
|
Cabnet Holdings Bhd
KLSE:0191
|
0.009x |
|
Vivid Games S.A
WAR:VVD
|
-0.050x |
|
Top Shelf International Holdings Ltd
AU:TSI
|
-0.324x |
|
Phoenix Motor Inc. Common Stock
NASDAQ:PEV
|
-0.277x |
|
Prg Holdings Bhd
KLSE:7168
|
-0.011x |
|
ERG S.A.
WAR:ERG
|
0.048x |
|
Ucloudlink Group Inc
NASDAQ:UCL
|
-0.337x |
Annual Cash Flow Conversion Efficiency for Check-Cap Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Check-Cap Ltd from 2016 to 2025. View current stock price of Check-Cap Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €3.44 Million ≈ $4.02 Million |
€-46.00K ≈ $-53.78K |
-0.013x | -100.24% |
| 2024-12-31 | €-1.45 Million ≈ $-1.70 Million |
€-8.00 Million ≈ $-9.36 Million |
5.520x | +871.22% |
| 2023-12-31 | €23.69 Million ≈ $27.69 Million |
€-16.95 Million ≈ $-19.82 Million |
-0.716x | -58.06% |
| 2022-12-31 | €41.31 Million ≈ $48.30 Million |
€-18.71 Million ≈ $-21.87 Million |
-0.453x | -41.13% |
| 2021-12-31 | €50.69 Million ≈ $59.26 Million |
€-16.26 Million ≈ $-19.01 Million |
-0.321x | +59.93% |
| 2020-12-31 | €16.38 Million ≈ $19.15 Million |
€-13.11 Million ≈ $-15.33 Million |
-0.801x | +61.14% |
| 2019-12-31 | €6.23 Million ≈ $7.29 Million |
€-12.84 Million ≈ $-15.01 Million |
-2.060x | -165.41% |
| 2018-12-31 | €13.03 Million ≈ $15.23 Million |
€-10.11 Million ≈ $-11.82 Million |
-0.776x | +48.99% |
| 2017-12-31 | €5.91 Million ≈ $6.90 Million |
€-8.99 Million ≈ $-10.51 Million |
-1.522x | -99.89% |
| 2016-12-31 | €10.41 Million ≈ $12.17 Million |
€-7.92 Million ≈ $-9.26 Million |
-0.761x | -- |
About Check-Cap Ltd
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology for the detection of precancerous colorectal polyps. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.